Novo Nordisk’s insulin degludec injection, known by the brand name Tresiba, met with FDA approval in late September. It is expected to be available to patients with a doctor’s prescription in the first few months of 2016, according to Novo Nordisk’s chief medical officer for North America, Dr. Todd Hobbs.

Read more